Formulation of human antibodies for treating TNF-alpha associated disorders
DCFirst Claim
Patent Images
1. A stable liquid aqueous pharmaceutical formulation comprising:
- a human anti-human Tumor Necrosis Factor alpha (TNFα
) IgG1 antibody at a concentration of 45 to 105 mg/ml, wherein the antibody is D2E7, and a buffer system;
wherein the formulation is isotonic, suitable for single-use subcutaneous injection, and has a pH of 4 to 8.
0 Assignments
Litigations
0 Petitions
Accused Products
Abstract
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
-
Citations
30 Claims
-
1. A stable liquid aqueous pharmaceutical formulation comprising:
- a human anti-human Tumor Necrosis Factor alpha (TNFα
) IgG1 antibody at a concentration of 45 to 105 mg/ml, wherein the antibody is D2E7, and a buffer system;wherein the formulation is isotonic, suitable for single-use subcutaneous injection, and has a pH of 4 to 8. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
- a human anti-human Tumor Necrosis Factor alpha (TNFα
Specification